Skip to content

Study · Measured the body's own peptide · 2019

4 results

New Metabolic Influencer on Oxytocin Release: The Ghrelin.

Szabó R, Ménesi R, H Molnár A, Szalai Z, Daruka L, Tóth G, Gardi J, Gálfi M, Börzsei D, Kupai K, Juhász A, Radács M, László FA, Varga C, Pósa A

Molecules (Basel, Switzerland)18 Feb 2019Cited by 10 (Europe PMC)

PMID30781678 (opens in a new tab)PMCIDPMC6413225 (opens in a new tab)DOI10.3390/molecules24040735 (opens in a new tab)PepBankPUB-30781678
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundThe hypothalamic⁻pituitary axis by secreting neuropeptides plays a key role in metabolic homeostasis. In light of the metabolic regulation, oxytocin is a potential neuropeptide for therapies against obesity and related disorders. The aim of our study is to measure ghrelin-induced oxytocin secretion in rats and to detect the changes after administration of ghrelin antagonist.MethodsGhrelin was administrated centrally (intracerebroventricular, i.c.v., 1.0, 10.0, and 100.0 pmol) or systemically (intravenous, i.v., 1.0, and 10.0 nmol). [d-Lys³]-GHRP-6 ghrelin antagonist was injected 15 min before ghrelin injection in a dose of 10.0 pmol i.c.v. and 10.0 nmol i.v.ResultsEither i.c.v. or i.v. administration of ghrelin dose-dependently increased the plasma oxytocin concentration. Following pretreatment with the ghrelin antagonist [d-Lys³]-GHRP-6, the high plasma oxytocin level induced by ghrelin was significantly reduced.ConclusionThe results indicate that the release of oxytocin is influenced directly by the ghrelin system. Examination of the mechanism of ghrelin-induced oxytocin secretion is a new horizon for potential therapeutic options.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, intracerebroventricular ghrelin dose-dependently increased plasma oxytocin concentration.

    In plain wordsIn rats, central ghrelin increased the body's own blood oxytocin levels in a dose-dependent manner.

    Peptide
    Oxytocin
    Outcome
    IncreasePlasma oxytocin after central ghrelin
    Study

    ratn: not reported in source

    rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Either i.c.v. or i.v. administration of ghrelin dose-dependently increased the plasma oxytocin concentration.
    1 context sentence
    Summary · context
    The aim of our study is to measure ghrelin-induced oxytocin secretion in rats and to detect the changes after administration of ghrelin antagonist.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, intravenous ghrelin dose-dependently increased plasma oxytocin concentration.

    In plain wordsIn rats, intravenous ghrelin increased the body's own blood oxytocin levels in a dose-dependent manner.

    Peptide
    Oxytocin
    Outcome
    IncreasePlasma oxytocin after systemic ghrelin
    Study

    ratn: not reported in source

    rats
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Either i.c.v. or i.v. administration of ghrelin dose-dependently increased the plasma oxytocin concentration.
    1 context sentence
    Summary · context
    The aim of our study is to measure ghrelin-induced oxytocin secretion in rats and to detect the changes after administration of ghrelin antagonist.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  3. 03AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, D-Lys-GHRP-6 pretreatment significantly reduced the high plasma oxytocin level induced by ghrelin.

    In plain wordsIn rats, D-Lys-GHRP-6 reduced the body's own oxytocin rise compared with ghrelin without antagonist pretreatment.

    Peptide
    Oxytocin
    Outcome
    DecreaseGhrelin-induced plasma oxytocin after antagonist pretreatment
    Study

    ratn: not reported in source

    rats
    Comparator
    Ghrelin without antagonist pretreatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Following pretreatment with the ghrelin antagonist [d-Lys³]-GHRP-6, the high plasma oxytocin level induced by ghrelin was significantly reduced.
    1 context sentence
    Summary · context
    The aim of our study is to measure ghrelin-induced oxytocin secretion in rats and to detect the changes after administration of ghrelin antagonist.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone1

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 04AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In rats, D-Lys-GHRP‑6 pretreatment significantly reduced the high plasma oxytocin level induced by ghrelin.

    In plain wordsIn rats, D-Lys-GHRP‑6 reduced blood oxytocin compared with ghrelin without antagonist pretreatment.

    Peptide
    GHRP-6
    Outcome
    DecreaseGhrelin-induced plasma oxytocin
    Study

    ratn: not reported in source

    rats
    Comparator
    Ghrelin without antagonist pretreatment
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Following pretreatment with the ghrelin antagonist [d-Lys³]-GHRP-6, the high plasma oxytocin level induced by ghrelin was significantly reduced.
    1 context sentence
    Summary · context
    The aim of our study is to measure ghrelin-induced oxytocin secretion in rats and to detect the changes after administration of ghrelin antagonist.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:13 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.